Pediatric Ventricular Tachycardia Overview of Ventricular Arrhythmias
Ventricular arrhythmia (VA) may be an isolated and completely benign finding in children, a marker of serious systemic disease or myopathy, or a mechanism for syncope and sudden cardiac death (SCD).
Isolated premature ventricular contractions (PVCs) are reasonably common. They occur with low daily frequency in as many as 40% of persons with apparently normal hearts. [1, 2, 3, 4] PVCs occur with increased frequency in more than 60% of patients with some types of repaired congenital heart disease (CHD).
By comparison, sustained VA is much less frequent. Although sustained VA can occur in apparently normal hearts, approximately 50% of patients have either CHD or myopathy. An increasingly sophisticated molecular understanding of the role of electrical myopathies, including ion-channel defects such as long QT syndrome (LQTS), offers increased insight into the nature of some of these diseases.
Clinical choices regarding imaging and therapy primarily focus on the potential mortality risks associated with the specific clinical setting. The incidence of SCD in pediatric patients is low. Even among patients with known heart disease, clinical decisions are challenging because of the potential risks of potent antiarrhythmic medications and of nonpharmacologic therapy (eg, catheter ablation, implantable antitachycardia pacemakers and/or defibrillators).
The prognosis cannot be generalized; it must be individualized and based on the underlying diagnosis.
Go to Ventricular Tachycardia for complete information on this topic.
Patients with VA and their families must know how to perform cardiopulmonary resuscitation (CPR) and how to contact local emergency medical services (EMS) to promptly begin therapy or prevent excessive therapy, as warranted. Not all patients need a home ambulatory external defibrillator (AED).
Reentrant, automatic, or triggered mechanisms may cause VA, just as these mechanisms cause supraventricular tachycardia (SVT) and other arrhythmias. Each of these mechanisms can occur in structurally and functionally normal hearts. Both myopericarditis and many forms of cardiomyopathy increase the potential for VAs. Myocardial tumors result in mechanical stresses that facilitate arrhythmias.
Reentrant arrhythmia depends on a circuit, often caused by surgical scar, fibrosis, or fatty degeneration. These areas of functionally abnormal tissue foster the conditions necessary for reentry. These conditions permit a zone of slow conduction, a line of functional unidirectional block, and a circuit that allows circus rhythm to continue.
Pediatric patients with surgical ventricular scars, such as those with postoperative ventricular tachycardia (VT) after repair of tetralogy of Fallot, are commonly cited examples of this mechanism. Chaotic rhythms (eg, ventricular fibrillation) are also examples of reentry mechanisms.
In clinical practice, reentrant rhythms are triggered by premature beats, and the tachycardia is often terminated with direct-current (DC) cardioversion. An abrupt onset and a generally stable rate are other characteristics of reentrant rhythms.
Automatic rhythms are more common than reentrant rhythms in pediatric patients with apparently normal hearts and are caused by abnormal cellular automaticity. The most frequent automatic rhythm is caused by increased spontaneous depolarization of phase 4 of the cardiac action potential.
Abnormal automaticity, in turn, may be the result of metabolic derangement, or the automaticity may be idiopathic. Metabolic derangements that may result in abnormal automaticity include hypokalemia, hypomagnesemia, and local cellular abnormalities (eg, inflammation from myocarditis). High atrial rates suppress, but do not eliminate, automatic VT. These rates vary with the autonomic state, often in complicated fashions. A benign accelerated idioventricular rhythm is an example of an autonomic mechanism.
At a cellular level, ion-channel defects, such as LQTS, allow abnormal cellular automaticity to trigger potentially fatal polymorphic VT, also known as torsade de pointes. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an increasingly recognized disorder, typically of the ryanodine receptor, characterized by exertionally triggered rapid atrial and ventricular tachycardia and ventricular fibrillation. Triggered arrhythmia may also play a role in poisoning by antiarrhythmic drugs (eg, digoxin). Go to Torsade de Pointes for complete information on this topic.
The frequency of VA entirely depends on the underlying substrate.
Large pediatric referral centers may encounter 3-5 patients with sustained VT each year.  The incidence of low-grade ectopy is notably increased in patients with CHD or cardiac myopathies.
Among patients with CHD, this incidence is concentrated among those who have had ventricular incisions (eg, ventricular septal defects, D-transposition with ventricular septal defects, tetralogy of Fallot) and aortic stenosis; as many as two thirds of patients in this population have some ectopy. This incidence appears to be increased in older patients, probably among those undergoing repair relatively late in life and with techniques used before the mid 1980s.
Although individual underlying myopathies are rare, each contributes to the overall incidence of VA. Hypertrophic cardiomyopathy (HCM) is most common, with a frequency as high as 0.02-0.2% of the population, although the population-based frequency among young people is generally lower.  Ion-channel defects (eg, LQTS) are less common; the frequency is difficult to quantitate but is probably approximately 1 case per 5000-10,000 persons. Despite the rarity of these conditions, each has an annual mortality risk as high as 3-5%.
The etiology of VA varies internationally. Chagas disease (trypanosomiasis) is an epidemic cause of dilated cardiomyopathy in Brazil and in other regions of South America.
In Europe, a heritable arrhythmogenic right ventricular dysplasia (ARVD) may be a leading cause of sudden death and VT in young people, particularly younger adults. The difference in perceived frequency likely results from a combination of genetic factors, variable definitions of ARVD, and differences in regional recognition of this entity.
No significant sex differences have been reported in overall incidence or severity of VA, though patterns of distribution of different LQTS genotypes may vary by sex. In addition, the implications of LQTS, HCM, ARVD, and other genetic cardiac defects appear to have some sex specificity.
Population-based studies in children have been relatively small but demonstrated a biphasic peak of simple ventricular ectopy in apparently healthy infants. This rate decreases during preschool and elementary school ages and increases with adolescence. As patients move into adult life, the incidence of ventricular ectopy continues to steadily increase (see the image below).
Although as many as 15% of infants and 40% of adolescents have infrequent ventricular ectopy, high-grade ectopy and VT are notably infrequent.
The incidence of VA is somewhat bimodal in patients without structural heart disease. Infants and adolescents have more cases of VA than do toddlers and younger school-aged children. The nature and classification of these cases also differs with age.
In patients with repaired CHD, incidence of VA is notably increased among older adolescents and young adults. This increase may reflect the management approach taken when these patients were younger, the long period after open-heart repair, and/or the influence of autonomic changes on the heart during adolescence.
The overwhelming majority of pediatric patients evaluated for nonsustained VA have no symptoms or only nonspecific palpitations. Obvious concerns include risk of cardiac syncope or SCD. This risk is low, except in selected patients with organic heart disease, for whom the annual risk of sudden death may be as high as 3% for those with sustained VT. The frequency distribution of sudden death in CHD overlaps with that of ventricular ectopy (see the image below).
Much concern regarding VA focuses on identifying preventable causes of SCD. The annual incidence of SCD in most clinically defined subgroups of pediatric patients is low. Nonselected pediatric populations have exceptionally low mortality rates (approximately 1-5 deaths per 100,000 patient-years).
In contrast, the annual sudden death rate in the general adult population is 1-3 deaths per 1000 patient-years; the annual mortality rate in adult survivors of myocardial infarction with depressed ventricular function and inducible, nonsuppressible VT is 20%.
For older patients with palliated heart disease or genetic arrhythmias, the risks are higher, although the rate is still usually no more than 1-3% annually. Issues of predicting low-frequency disease—difficult issues in any setting—are magnified in the population with CHD and particularly in the overall pediatric population. Current data suggest that impaired ventricular function and symptoms are both critical risk factors in identifying those patients in whom ventricular arrhythmias are more likely to be either a cause of cardiac arrest or marker of vulnerability. The converse is also true, that for simple heart disease with good ventricular function, overall mortality rates in adolescence and young adulthood are very low, in the range of 0.1% per year or lower.
Among infants and children with minimal symptoms and normal ventricular function (and even very frequent VA, including VT), most have spontaneous resolution of their arrhythmia, with little intercurrent morbidity. [7, 8, 9, 10, 11]
Data about the influence of race in pediatric SCD are limited. Incidences of some heritable myopathies vary by ethnic group. Despite these variations, most diagnoses should be considered in all ethnic groups.
The incidence of LQTS appears to be decreased in blacks, and ARVD appears most frequent in patients of southern European ancestry. Although Brugada syndrome has been identified in many ethnic groups, it is identical to the sudden unexpected nocturnal death syndrome identified in men of Southeast Asian ancestry.
The following historical details raise particular concern for ventricular arrhythmia (VA):
Presence and severity of symptoms
Presence of symptoms with exercise
Previous cardiac diagnoses and procedures
Family medical history suggestive of inherited disease
Potential for recent medication or recreational drug use
In the pediatric population, neurally mediated syncope is so common—and life-threatening arrhythmia is so rare—that investigations of VA in patients with syncope are often unrevealing. Details of the history and family history can direct additional, extensive investigation. Diagnostic findings such as “class II” genetic mutations, which may represent pathologic findings, or nonreproducible findings during intracardiac studies may represent false positives.
A family history of sudden death before age 40 years should raise suspicions, even if the cause was an apparent accident. Numerous familial low-incidence cardiomyopathies have arrhythmia as an important symptom. These cardiomyopathies are characterized by several phenotypes and variable penetrance. When a potentially genetic disorder is identified, careful family investigation can identify other affected families members. The reported yields vary but may approach 50%.
Precipitating events may include the following:
Use of prescription or recreational drugs (eg, cocaine)
Recent surgical procedures
Central lines (eg, direct mechanical ectopy)
Recent illnesses (eg, potential for myocarditis); fever may be a potent trigger for VA associated with Brugada syndrome 
Prescription drugs that may precipitate VA include tricyclic antidepressants (especially in overdose), and antiarrhythmia medications. Web sites that offer useful references about other drugs that affect repolarization include the following:
The initial 1998 American Heart Association (AHA) Scientific Statement, Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs
Newer documents have included a comprehensive review of pediatric arrhythmia risks and suggest a more controversial screening practice. These include Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder. This approach has not been endorsed by either the American or Canadian Pediatric Societies.
Perform a detailed cardiac examination. Focus on clinically apparent arrhythmia and physical signs of heart failure or structural heart disease. Normal results do not exclude serious or life-threatening disease.
In the general physical examination, particularly focus on evidence of occult or apparent skeletal myopathy, neurocutaneous syndromes, rickets, and previous procedures.
Apparent cardiac syncope consistently increases the potential of identifying a life-threatening disease that requires active management. Cardiac syncope, in contrast to typical neurally mediated syncope, is characterized by abrupt onset associated with exercise, clinically significant injury, incontinence, seizure, and rapid recovery when arrhythmia is transient.
Palpitations are common in both neurally mediated and cardiac syncope. During benign episodes, these palpitations are often described as hard beats at lower rates, compared with the rapid pulse identified when tachycardia triggers syncope.
Syncope in the presence of known or apparent heart disease should be presumed to represent a potentially serious arrhythmia until proven otherwise. New onset of syncope and VAs may be particularly worrisome.
The vast majority of patients with episodic dizziness, light-headedness, or other presyncopal symptoms have benign or self-limited diagnoses. Clinical correlation is critical when presyncopal symptoms are associated with ventricular ectopy or other arrhythmia.
Patients with isolated premature ventricular contractions (PVCs) and those with sustained arrhythmia may report symptomatic palpitations. Particularly with PVCs, the postextrasystolic beat may have an increased stroke volume.
Of note, many patients do not report any symptoms and cannot identify when they are having ventricular beats. Like syncope, palpitations frequently occur in patients without significant arrhythmia. Ambulatory ECGs (eg, those recorded with Holter or memory-looping event monitors) are critical tools to correlate symptoms and rhythm.
Most chest pain is clearly of musculoskeletal origin (costochondritis). Physical examination in these cases reveals reproducible point tenderness and no clinical suggestion of heart disease.
Another common scenario is atypical chest pain, which is described as brief, sharp, and stabbing. This finding is poorly correlated with exercise and not correlated with the ECG.
Chest pain may represent a marker of hypertrophic cardiomyopathy (HCM) or relatively common diagnoses. Typical angina is extremely rare.
Sudden cardiac death (SCD) and rare cases of coronary artery disease are clearly related in some way. VA may be secondary to Kawasaki disease, congenital coronary anomalies, or typical angina.
Pediatric chest pain is typically poorly defined and may include arrhythmia symptoms, pulmonary symptoms, or GI symptoms in addition to anxiety. In pediatric patients, unlike older adults, the serious cardiac causes of chest pain are all rare, which influences both the need for additional testing and the yield of that testing.
Sustained VT is defined as consecutive ventricular rhythm longer than 30 seconds at rates faster than 110-120 bpm or a comparable arrhythmia requiring urgent cardioversion.
Nonsustained VT includes 3 or more consecutive beats lasting less than 30 seconds. High-grade ventricular ectopy is the VA classification that includes combinations of ventricular couplets and polyform premature ventricular contractions (PVCs), which are more frequent than isolated PVCs and less sustained than VT.
Long QT syndrome is a familial ion-channel defect caused by a microdeletion; deletions in chromosomes 3, 4, 7, 11, and 21 have been identified. Although each defect is unique, they share a tendency to abnormal repolarization and an increased risk of sudden death associated with torsade de points.
High-dose beta-blockade has been a mainstay therapy for years. Novel approaches with atrial pacing, implantable cardioverter/defibrillators (ICDs), and gene-specific ion-channel manipulation may help certain patients.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is the most frequent diagnosis in southern Europeans who die during exercise. This complex and heterogeneous myopathy is associated with fatty degeneration (replacement) of the right ventricular myocardium and inducible VA.
Hypertrophic cardiomyopathy (HCM) may result in SCD, apparently mediated by VT, in young people. High-grade ectopy, as shown on Holter monitoring, is an apparent risk factor for SCD in adults with HCM; however, this finding provides little assistance to pediatric patients. Correlation in genotype-positive families with HCM suggests that as many as a quarter of children and adolescents with mild or early forms of HCM may be missed during ECG screening. 
Arrhythmia and mortality risks associated with hypertrophic cardiomyopathy vary widely. Data from population-based pediatric studies and the pediatric cardiomyopathy registry suggest that the risk for older children and adolescents with HCM is 1% per year or less.  Infants and those with inborn errors of metabolism represent patients with notably increased risk.
Brugada syndrome represents another identifiable genetic defect (of the sodium channel) that causes VAs. Patients with this syndrome tend to present with a pattern of right bundle-branch block (RBBB) on resting ECG and ST-segment elevation. Both fever and a full stomach may be important triggers of the pattern, and fever is a frequent contributor to childhood events. [14, 12]
Catecholaminergic polymorphic VT is yet another identifiable ion-channel defect that occurs on a relatively frequent familial basis, with recurrent polymorphic VT, a normal resting ECG, and normal repolarization. Genetic studies have identified patients and families with mutations in the ryanodine receptor, among other gene defects. These patients often have atrial and junctional arrhythmias along with relative sinus bradycardia.
Acute viral myocarditis with depressed ventricular function and active inflammation, whatever the etiology, can cause ventricular ectopy and VT. Short-term drug therapy to suppress arrhythmia is indicated while myocarditis is managed.
In cases with profound ventricular dysfunction, urgent transfer for consideration of mechanical support may be life saving.
Arrhythmias may persist well after the hemodynamic dysfunction has resolved.
Although infrequent, cases of focal or occult myocarditis associated with VA have been well documented. Some patients with frequent ectopy or idiopathic VT may also have subclinical myocarditis. Functional imaging studies and endomyocardial biopsy may help identify these patients.
Idiopathic arrhythmias have characteristic patterns but occur in patients who do not have the diagnoses outlined above.
Benign arrhythmia is always diagnosed with caution on the basis of the symptoms, family history, echocardiogram, response to and rate of exercise, morphology, and persistence of the arrhythmia.
Idiopathic arrhythmias include the following:
Right ventricular outflow tract VT
Accelerated idioventricular rhythm
Infrequent, isolated PVCs, particularly with a trigger such as anesthesia or an intracardiac catheter, require little investigation. PVCs notably more frequent than expected for the patient’s age may warrant investigation to seek evidence of sustained arrhythmia.
Right ventricular outflow tract VT is frequently asymptomatic. This arrhythmia has a left bundle-branch block (LBBB) morphology, often-repetitive salvos of VT, possibly subtle MRI findings, and low-to-absent mortality. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is often a difficult diagnostic challenge. Even in families with clear, genetically mediated ARVC, the phenotype is often silent during the pediatric period.
RBBB VT may be automatic. Some occurrences may be reentrant VT triggered by atrial pacing or atrial premature beats. This clearly triggered pattern is more likely to be associated with the left ventricular hemifascicles. This arrhythmia is seen in patients of all ages. RBBB VTs often respond to intravenous verapamil therapy. 
Accelerated idioventricular rhythm is typically seen in infants and young children, accelerated idioventricular rhythm rates are slightly faster than sinus beats. LBBB is usually seen, suggesting a right ventricular focus. No mortality has been reported with this condition, and therapy is infrequently needed. Carefully observe affected infants for evidence of increasing VT or decreasing function.
PVCs are seen in as many as two thirds of adolescents and young adults with moderate-to-severe valvar aortic stenosis or repaired tetralogy of Fallot. PVCs are also seen in some patients with ventricular septal defects and in patients with irreparable heart disease, especially those with pulmonary hypertension. In the absence of symptoms, these findings are best interpreted by understanding the hemodynamics of the underlying illness.
The classifications of nonsustained and sustained VT in patients with CHD are identical to those of patients with structurally normal hearts. These classifications should be considered in the context of the patient’s symptoms and current hemodynamic status.
The presence of clinical VT and, in some settings, VT induced during electrophysiologic testing, may be independent of other hemodynamic defects in predicting the risk of cardiac arrest and mortality. Careful consultation and evaluation is appropriate.
Tetralogy of Fallot, the defect most commonly associated with spontaneous or induced monomorphic VT, the occurrence of VT is strongly associated with increasing age, increasing age at initial repair, and residual hemodynamic defects. Management choices are complex and may include drug therapy, ICD therapy, ablation, or management of residual hemodynamic issues.
The most devastating risk is sudden cardiac death or aborted sudden death with subsequent hypoxic-ischemic brain injury. Incessant arrhythmia may induce reversible myopathy, and even transient arrhythmic events produce syncope that results in traumatic injury.
Mechanical causes of VAs include the following:
Metabolic causes of VAs include the following:
Pharmacologic causes of VAs include the following:
Most antiarrhythmia drugs (especially classes I-A, I-C, III)
Positive inotropes and chronotropes (eg dopamine, isoproterenol)
Other drug toxicity
Inflammatory causes of VAs include the following:
Electrical myopathies that may cause VAs include the following:
Long QT syndrome
Catecholaminergic polymorphic ventricular tachycardia (VT)
Other causes of VAs include the following:
Dilated or hypertrophic cardiomyopathy – Muscular dystrophy, IHSS
Structural cardiac disorders – Congenital heart disease (CHD)
Problems to be considered in diagnosing VA include the following:
Premature ventricular beats
Idioventricular, ventricular, or escape beats or rhythm
Supraventricular tachycardia with aberration
Supraventricular tachycardia with fixed interventricular conduction defect
Supraventricular tachycardia with bystander pre-excitation
Antidromic reciprocating tachycardia
There are relatively well-defined algorithms for helping sort through this differential from standard ECGs in older adults. These algorithms are less reliable in pediatric patients, in whom a higher frequency of stable wide complex tachycardia will turn out to be SVT. 
See the image below.
An ECG with a rhythm strip allows for a rapid initial analysis of the morphology, frequency, and electrical substrate of suspected arrhythmia. ECG helps to exclude supraventricular tachycardia (SVT) or atrial arrhythmias with fixed bundle-branch block (BBB) or rate-dependent aberrancy. Leads aVF, V1, and V6 provide sufficient data to classify BBB morphology and estimate frontal-plane axes.
In combination with ambulatory or bedside monitoring systems, ECG provides sufficient data for initial diagnosis of most VAs.
A 24-hour Holter evaluation provides a quantitative daily snapshot of ventricular ectopy. In patients with suspected cardiac syncope, pay particular attention to QT intervals and T-wave changes for hints of underlying disease. The Holter QTc and ECG measurement of QTc do not have a 1:1 correlation; good data are not available regarding absolute QT/QTc measurements using the rapid sweep speed and high gain typically used in Holter monitoring.
Episodic correlation is best performed by using a memory-looping event monitoring system. Some memory-looping monitors are worn and make continuous recordings. These devices record and hold the waveform before patients activate them.
Other nonlooping “memo” versions are not worn continuously. These systems do not record continuously. Instead, they are activated on symptom onset and, therefore, frequently miss the symptomatic event. They are quite effective in patients with sustained arrhythmias.
Memory-looping systems are preferable for assessment of nonsustained arrhythmias or evanescent symptoms because they can capture the start of a rhythm and because they are most likely to be recording during symptoms. The yield on either system declines rapidly after 2-3 weeks of use.
New surgically implantable, subcutaneous systems may allow for the correlation of symptoms and rhythms in selected patients. [17, 18] Continuous multilead home telemetry is now marketed as a way in increasing the yield of ambulatory monitoring. 
Exercise typically suppresses benign arrhythmia. In contrast, increasing arrhythmia density and complexity with exercise suggests more problematic mechanisms.
Repeated exercise tests may help in assessing the adequacy of medication and other therapeutic choices. Treadmill exercise is generally more effective at recreating arrhythmias and permits more effective evaluation of blood pressure adaptation in hypertrophic cardiomyopathy (HCM), syncope, and other clinical scenarios.
Overall, exercise testing enhances the sensitivity of ECG monitoring, although it has uncertain reproducibility and specificity.
In adults with decreased left ventricular function, the presence of microvolt T-wave alternans is strongly associated with both ventricular arrhythmias and sudden cardiac arrest. In the pediatric population, although T-wave alternans do seem to be associated with serious VAs, other variables offer more information. In both populations, the absence of microvolt T-wave alternans appears to help select patients at lower risk.  Reimbursement and technical issues have limited the use of the test.
Commercial systems permit relatively easy acquisition of signal-averaged ECGs and identification of late potentials. Many high-risk patients with CHD have BBBs or paced rhythms, making the test invalid. Like T-wave alternans, the test is not widely used, with the exception of longitudinal evaluation of patients with suspected ARVC.
Acute symptomatic or sustained VA generally warrants relatively intensive laboratory investigation. Nevertheless, the yield of these tests is typically low when the history, physical findings, and other aspects of the patient’s presentation do not suggest specific findings. Most of these studies are omitted in patients with asymptomatic arrhythmia with apparently normal hearts.
Hyperkalemia and hypokalemia, regardless of their cause, are associated with increasing ventricular ectopy and may affect repolarization. Severe hypocalcemia, as seen in rickets, can prolong QT intervals and permit polymorphic ventricular tachycardia (VT).
Hypomagnesemia may be clinically important in patients with cardiac conditions during the immediate postoperative period and in certain other settings.
Administration of multiple therapeutic drugs or abuse of recreational drugs can trigger VA. Pay particular attention to tricyclic antidepressant overdose, use of drugs that may affect the potassium channel (eg, cisapride), and stimulant ingestion.
Although typically associated with other clinical features of hyperthyroidism, elevated thyroxine levels may increase a patient’s underlying arrhythmia or may trigger a new arrhythmia. Pay particular attention to thyroid function in patients with a history of amiodarone use.
Other laboratory data, including transaminases and bilirubin levels, may be required to make decisions about drug therapy. Both arterial blood gases and central venous oxygen saturations may help in assessing the hemodynamic severity of arrhythmia in some patients. See the Oxygen Content of Venous Blood calculator.
Genetic testing is now commercially available for many of the genes related to hypertrophic cardiomyopathy (HCM), long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic VT. Even with clear clinical diagnoses, as many as 30% of patients with LQTS have negative results on genetic testing, and as many as 80% of patients with Brugada syndrome have negative results on testing.
Limited testing is also available for arrhythmogenic right ventricular cardiomyopathy(ARVC). Updated genetic testing data are summarized on the GeneTests Web site. Some insurers do not cover these tests, which can result in prohibitively expensive charges.
Perform family screening when the results of initial patient assessment suggest familial disease (eg, HCM, LQTS). Genetic testing is exceptionally valuable when evaluating an extended family where the gene is clearly identified and testing can be narrowly focused.
For an individual patient with clinical ambiguity genetic testing remains a tool that often requires detailed judgment. With LQTS, a significant number of mutations are reported that have not been demonstrated to have adverse clinical or cellular electrophysiology effects.
Chest radiography allows for a rapid assessment of ventricular dilatation, pulmonary venous pressure, and mechanical influences (eg, intracardiac catheters). With ready access to echocardiography, the importance of chest radiography has decreased.
All patients with clinically significant ectopy should undergo a complete echocardiographic examination, ideally in a laboratory skilled in examining children. The following specific details may be sought:
Ventricular function (on sinus beats)
Wall thickness and chamber dimensions
Proximal coronary artery pattern, including efforts to visualize Doppler flow
Structural heart disease
The use of MRI is evolving. Although indications for MRI are uncertain, cardiac MRI is used primarily to assess arrhythmogenic right ventricular dysplasia (ARVD) myocarditis utilizing intravenous gadolinium and tumors. However, data from critical analysis suggest that MRI may result in overdiagnosis of ARVD.  Not surprisingly, the test is quite reasonable in adult patients who already meet Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC). 
When the rhythm is irregular, gating may be insufficient to acquire adequate images. Specific techniques involving delayed enhancement may improve discrimination.
Selected patients may be given serial trials of drugs to either provoke or suppress arrhythmia.
Cardiac catheterization is generally reserved for patients with severe symptoms or arrhythmia in whom adequate diagnosis and risk assessment are impossible with noninvasive testing. The asymptomatic patient with infrequent arrhythmias and normal ventricular function or the patient with a clear diagnostic pattern does not routinely need catheterization and invasive EP testing.
Patients with ventricular ectopic rhythms, particularly those with depressed function, may have myocarditis that warrants therapy.
Although echocardiography and other noninvasive tests are excellent, catheterization provides a measurement of hemodynamics in patients with VA who undergo catheterization for other indications.
Except in selected patients with premature coronary artery disease (eg, after heart transplantation), the primary issue is whether abnormalities are present in the origin of the coronaries and in their proximal course. Selective coronary angiography is often necessary to address this issue. Echocardiography, high-resolution CT, and cardiac MRI are excellent noninvasive imaging tools to visualize the proximal coronary arteries.
Right ventriculography may help to diagnose arrhythmogenic right ventricular dysplasia (ARVD) and facilitate mapping studies.
Programmed atrial and ventricular stimulation are reasonably effective in reproducing reentrant VA. For patients with CHD, [25, 26] suspected Brugada syndrome, or suspected arrhythmogenic right ventricular dysplasia (ARVD), programmed stimulation may assist in risk stratification or diagnosis.
Voltage mapping in ARVD may assist in identifying areas of low amplitude ventricular signals in the right ventricular free wall and septum that represent substrates for reentry.
Intracardiac recordings and the use of temporary or esophageal wires allow for a firm diagnosis when surface ECGs are unclear.
Programmed stimulation is typically not useful for triggering or excluding automatic ventricular rhythms, which are most common in childhood and adolescence.
Histologic findings depend on the ultimate diagnosis. Many patients with serious arrhythmia have entirely normal results on light and electron microscopy. Fibrosis or inflammation may influence therapy.
Therapy may not be needed in asymptomatic patients whose VT patterns suggest a low risk of sudden death. Symptoms or a clinically significant short-term risk of SCD frequently warrants admission for evaluation and consideration of therapeutic options.
Initial therapy for ventricular fibrillation is immediate, unsynchronized direct current (DC) defibrillation. Data suggest that a brief (ie, 90 s) period of chest compressions may improve survival when ventricular fibrillation is witnessed, but immediate defibrillation is the therapy of choice. Do not waste time on other aspects of resuscitation before initial defibrillation, unless defibrillation is unavailable.
Identify and target potential substrates for arrhythmia-specific therapy.
Optimal inpatient management is performed with secure vascular access and continuous cardiac monitoring. In the ideal case, cardiac monitoring systems are connected to a central monitoring station in a cardiac care unit or ICU. Simple bedside monitors with high-rate and low-rate alarms are inadequate to monitor patients with the potential for unstable VA. For unstable patients, conduct simultaneous evaluation and therapy.
For hemodynamically stable patients, evaluation is followed by serial drug therapy. Diagnostic or therapeutic catheterization also may be performed.
Although antiarrhythmic drug therapy can suppress spontaneous arrhythmia and although it may help individual patients, some of these medications have resulted in increased mortality rates in selected adult and pediatric patients. Mortality rates typically increase when the overall risk of the arrhythmia is less than the proarrhythmia risk of the drug. Estimates of both are problematic in pediatrics.
Although digoxin is approved for use in infants, it lacks specific antiarrhythmic properties that aid in the control of most ventricular arrhythmias. All other agents, despite the current use, are not approved for use in young children.
Antiarrhythmic drug therapy is further complicated because no single drug is ideal in all settings. Beta-blockade, with intravenous (IV) esmolol or any of the oral (PO) preparations, is a good initial choice for nearly all forms of VA. In addition, it has few absolute contraindications in the treatment of serious arrhythmia.
Other medications have important limitations. Many are negative inotropes and all have important drug and metabolic interactions.  Use of verapamil in children younger than 1 year is associated with infrequent episodes of cardiovascular collapse and death. Procainamide is an excellent choice for incessant reentrant VA in many settings, but it may exacerbate long QT syndrome (LQTS).
Oral agents in Vaughn-Williams class I-A (eg, quinidine, procainamide), class I-C (eg, flecainide, propafenone), or class III (eg, sotalol, amiodarone) can cause ventricular proarrhythmia and suppress clinical arrhythmia while increasing mortality rates in selected populations.
Amiodarone is generally reserved for potentially life-threatening VA. Both IV and oral amiodarone may have important noncardiac adverse effects. Make therapeutic decisions carefully after consulting with an experienced pediatric cardiologist (electrophysiologist).
Intravenous amiodarone in infants and young children deserves particular attention. The medication’s broad efficacy and ready availability has increased its popularity in managing sustained arrhythmias in the ICU and emergency setting. A prospective tiered dose pediatric trial showed good efficacy but a nearly 50% incidence of major adverse events. 
Neonates may have relatively frequent episodes of nonsustained ventricular tachycardia or, more precisely, accelerated idioventricular rhythm (AIVR). Although thorough noninvasive evaluation with monitoring and echocardiography is warranted, the risk of mortality is probably zero. Similarly, the risks associated with many forms of VA are quite low in the patient without cardiomyopathy or a probable ion-channel defect.
In both of these settings, avoiding therapy with potentially risky drugs and then choosing an agent that is more effective at decreasing arrhythmias on ambulatory monitoring may be important.
Propranolol, atenolol, nadolol, and esmolol are the beta-blockers most frequently used to manage VA. They appear to be particularly effective in treating patients with VA, LQTS, or HCM. Other agents may be useful; sotalol, propafenone, and amiodarone have beta-blocking properties. Beta-blockers have not been associated with ventricular proarrhythmia; this is a major advantage of this class compared with other agents, particularly class I and III agents. Base the choice between beta-blockers on the duration of action, selectivity, and preparation.
This class of agents has complex actions. The drugs primarily block sodium channels, decreasing conduction velocity (QRS widening). Only IV procainamide and lidocaine are presented here. Quinidine, the initial drug in this class, is associated with excessive ventricular proarrhythmia in most patient groups.
Propafenone, disopyramide, flecainide, and other agents may have a role in long-term therapy in some patients. Some children, and adults with ischemic heart disease have increased mortality rates while taking these medications despite apparent control of their arrhythmia. Interesting data suggest that flecainide may offer specific therapy for some patients with CPVT. 
Selected patients require highly individualized interventional procedures, such as the following:
Radiofrequency catheter ablation or cryoablation
Left cervical sympathectomy
Myocardial tumor resection
Incessant VT is sometimes secondary to focal lipoid cardiomyopathy, isolated fibromas, or hamartomas. In selected patients, surgical excision may be both diagnostic and therapeutic. 
ICDs have revolutionized the care of adults with high-risk VT after myocardial infarction. ICDs are increasingly used in high-risk pediatric patients. [31, 32, 33] Transvenous systems have been used in patients who weigh as little as 20 kg. In highly selective situations, toddlers and large infants have received epicardial systems implanted through a sternotomy.  Creative, hybrid approaches are further increasing clinicians’ willingness to use ICDs in young patients (see the image below).
Both catheter-directed radiofrequency ablation and intraoperative resection or cryoablation of VT foci have been successful with monomorphic VTs; however, their use is unproved for patients with polymorphic VT.
Unlike supraventricular arrhythmias, for which catheter ablation has a more than 95% success rate, VT ablation in pediatric patients and in patients with CHD has a success rate of about 60%. [35, 36] Both a lack of arrhythmia and proximity to the bundle of His limit the ability to provide effective therapy. [37, 15, 38]
For many years, left cervical sympathectomy was performed for refractory long QT syndrome. The use of video-assisted/minimally invasive techniques has increased the use of this therapy for patients with long QT, CPVT, and recurrent symptomatic arrhythmias. Often this is subsequent to ICD placement. [39, 40, 41]
Primary care physicians may certainly observe patients with infrequent asymptomatic premature ventricular contractions (PVCs), often with a 24-hour Holter evaluation, to confirm the frequency and severity of arrhythmia. For most other patients with VA more complex than this, prompt referral and direct communication with a pediatric cardiologist is indicated. Referral facilitates appropriate testing and decision making about evaluating the patient on an inpatient or outpatient basis.
The patterns and relative risks of arrhythmia in adult and pediatric patients differ substantially. Whenever feasible, a cardiologist with specific training and expertise in pediatric heart disease should evaluate the patient. Expedite referral when any of the following indications are present:
Symptoms of syncope or apparent heart failure
Family history of premature death or seizures
History or physical suggesting structural heart disease or heart failure
Arrhythmia triggered by medications
Arrhythmia triggered by recreational drugs
Nonsustained or sustained VT
History of cardiac surgery or known heart disease, even if it is apparently repaired
Diet is rarely is a factor in VA. Diuretic use or abuse, anorexia, or chronic diarrhea can induce hypokalemia, which exacerbates VA. Primary or dietary rickets rarely produces sufficient hypocalcemia to cause QT prolongation and a risk of arrhythmia.
The updated 2005 Bethesda conference offers a useful initial set of recommendations for patients with ventricular ectopy. 
In the absence of detailed investigations and referral, the activity of patients with PVCs that are more than isolated is typically restricted to low-static or low-dynamic activities. Similar restrictions are recommended for those with clinically significant ectopy and most forms of heart disease or symptoms. Patients whose findings on subsequent investigation suggest benign VT often may resume their full activities.
Detailed recommendations for both patients with inherited heart disease and those with CHD have been updated in the 36th Bethesda Conference. 
Exercise represents a paradox because its long-term health benefits may lower the overall incidence of cardiac events, but the instantaneous risk of cardiac events appears to increase during or immediately after exertion. Some patients with prolonged-QT syndrome have drowned, particularly after diving into cold water, presumably because they developed ventricular fibrillation.
Elite athletes, particularly males, may have an athletic heart syndrome that can include mildly increased left ventricular mass with normal left ventricular cavity dimensions. One third of these patients have more than 100 premature ventricular beats per 24 hours with other higher-grade ectopy, including couplets and nonsustained VT.
Admit patients with new and unprotected symptoms of apparent cardiac syncope to a monitored setting to ensure their safety during evaluation.
Perform intracardiac procedures, some of which may be performed as same-day admissions. Revise or place implantable defibrillators. Initiate antiarrhythmic therapy.
Patients with conditions beyond asymptomatic, isolated, premature ventricular beats should receive episodic monitoring of their clinical status. They may require repeated assessment of ventricular function with echocardiography, repeated Holter or event monitoring, and monitoring for drug effects when drugs are used.
Device-based therapy requires a follow-up system to evaluate and manage the consequences and complications of therapy.
Patients with apparent cardiac syncope and VA require prompt evaluation by a cardiologist. Transfer the patient to a setting that can ensure adequate monitoring, skilled nursing, and an experienced pediatric cardiology team.
For many rhythms, complete suppression is neither warranted nor advisable. Carefully monitor the administration of drugs that affect repolarization (eg, cisapride, major antipsychotics, tricyclic antidepressants) because monitoring may decrease the risk of torsade de pointes in patients taking these medications.
Prudent preventive measures for patients with VA include avoiding known triggers and sustained drug use, especially recreational drug use.
Therapy with beta-blockers and possibly other medications may help decrease the risk in patients with HCM and in symptomatic patients with LQTS. No particular therapy clearly prolongs survival in high-risk patients with dilated cardiomyopathy or CHD.
Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol. 1977 Mar. 39(3):390-5. [Medline].
Sobotka PA, Mayer JH, Bauernfeind RA, et al. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J. 1981 Jun. 101(6):753-9. [Medline].
Jacobsen JR, Garson A Jr, Gillette PC, McNamara DG. Premature ventricular contractions in normal children. J Pediatr. 1978 Jan. 92(1):36-8. [Medline].
Nagashima M, Matsushima M, Ogawa A, et al. Cardiac arrhythmias in healthy children revealed by 24-hour ambulatory ECG monitoring. Pediatr Cardiol. 1987. 8(2):103-8. [Medline].
Roggen A, Pavlovic M, Pfammatter JP. Frequency of spontaneous ventricular tachycardia in a pediatric population. Am J Cardiol. 2008 Mar 15. 101(6):852-4. [Medline].
Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007 Feb 13. 115(6):773-81. [Medline].
De Rosa G, Butera G, Chessa M, et al. Outcome of newborns with asymptomatic monomorphic ventricular arrhythmia. Arch Dis Child Fetal Neonatal Ed. 2006 Nov. 91(6):F419-22. [Medline].
Davis AM, Gow RM, McCrindle BW, Hamilton RM. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Am Heart J. 1996 Jan. 131(1):186-91. [Medline].
Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coll Cardiol. 1999 Jun. 33(7):2067-72. [Medline].
Van Hare GF, Stanger P. Ventricular tachycardia and accelerated ventricular rhythm presenting in the first month of life. Am J Cardiol. 1991 Jan 1. 67(1):42-5. [Medline].
Harris KC, Potts JE, Fournier A, et al. Right ventricular outflow tract tachycardia in children. J Pediatr. 2006 Dec. 149(6):822-826. [Medline].
Antzelevitch C, Patocskai B. Brugada syndrome: clinical, genetic, molecular, cellular, and ionic aspects. Curr Probl Cardiol. 2016 Jan. 41 (1):7-57. [Medline].
Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J. 1998 Sep. 19(9):1377-82. [Medline].
Southall DP, Richards J, Mitchell P, et al. Study of cardiac rhythm in healthy newborn infants. Br Heart J. 1980 Jan. 43(1):14-20. [Medline].
Kilic E, Celiker A, Karagoz T, Alehan D, Ozkutlu S, Ozer S. Analysis of idiopathic ventricular tachycardia in childhood. Turk J Pediatr. 2012 May-Jun. 54(3):269-72. [Medline].
Ceresnak SR, Liberman L, Avasarala K, Tanel R, Motonaga KS, Dubin AM. Are wide complex tachycardia algorithms applicable in children and patients with congenital heart disease?. J Electrocardiol. 2010 Nov-Dec. 43(6):694-700. [Medline].
Frangini PA, Cecchin F, Jordao L, et al. How revealing are insertable loop recorders in pediatrics?. Pacing Clin Electrophysiol. 2008 Mar. 31(3):338-43. [Medline].
Kothari DS, Riddell F, Smith W, Voss J, Skinner JR. Digital implantable loop recorders in the investigation of syncope in children: benefits and limitations. Heart Rhythm. 2006 Nov. 3(11):1306-12. [Medline].
Saarel EV, Doratotaj S, Sterba R. Initial experience with novel mobile cardiac outpatient telemetry for children and adolescents with suspected arrhythmia. Congenit Heart Dis. 2008 Jan. 3(1):33-8. [Medline].
Alexander ME, Cecchin F, Huang KP, Berul CI. Microvolt t-wave alternans with exercise in pediatrics and congenital heart disease: limitations and predictive value. Pacing Clin Electrophysiol. 2006 Jul. 29(7):733-41. [Medline].
Bomma C, Rutberg J, Tandri H, et al. Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2004 Mar. 15(3):300-6. [Medline].
Tandri H, Calkins H, Nasir K, et al. Magnetic resonance imaging findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2003 May. 14(5):476-82. [Medline].
Tandri H, Bluemke DA, Ferrari VA, et al. Findings on magnetic resonance imaging of idiopathic right ventricular outflow tachycardia. Am J Cardiol. 2004 Dec 1. 94(11):1441-5. [Medline].
Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998 Jul. 32(1):245-51. [Medline].
Alexander ME, Walsh EP, Saul JP, et al. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol. 1999 Aug. 10(8):1033-44. [Medline].
Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004 Apr 27. 109(16):1994-2000. [Medline].
Brugada J, Blom N, Sarquella-Brugada G, et al for the European Heart Rhythm Association and Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013 Sep. 15(9):1337-82. [Medline].
Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005 Nov 29. 112(22):3470-7. [Medline].
Jacquemart C, Ould Abderrahmane F, Massin MM. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2012 Nov-Dec. 45(6):736-8. [Medline].
Miyake CY, Del Nido PJ, Alexander ME, et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol. 2011 Oct 25. 58(18):1903-9. [Medline].
[Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27. 51(21):e1-62. [Medline].
Alexander ME, Cecchin F, Walsh EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004 Jan. 15(1):72-6. [Medline].
Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008 Apr 29. 51(17):1685-91. [Medline].
Stephenson EA, Batra AS, Knilans TK, et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol. 2006 Jan. 17(1):41-6. [Medline].
Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm. 2004 Sep. 1(3):301-8. [Medline].
Laohakunakorn P, Paul T, Knick B, et al. Ventricular tachycardia in nonpostoperative pediatric patients: role of radiofrequency catheter ablation. Pediatr Cardiol. 2003 Mar-Apr. 24(2):154-60. [Medline].
Collins KK, Schaffer MS, Liberman L, et al. Fascicular and nonfascicular left ventricular tachycardias in the young: an international multicenter study. J Cardiovasc Electrophysiol. 2013 Jun. 24(6):640-8. [Medline].
Pokushalov E, Romanov A, Turov A, Artyomenko S, Shirokova N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2010 Oct. 7(10):1406-10. [Medline].
Coleman MA, Bos JM, Johnson JN, et al. Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome. Circ Arrhythm Electrophysiol. 2012 Aug 1. 5(4):782-8. [Medline].
Atallah J, Fynn-Thompson F, Cecchin F, DiBardino DJ, Walsh EP, Berul CI. Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg. 2008 Nov. 86(5):1620-5. [Medline].
Collura CA, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm. 2009 Jun. 6(6):752-9. [Medline].
Zipes DP, Ackerman MJ, Estes NA, et al. Task force 7: arrhythmias. J Am Coll Cardiol. 2005 Apr 19. 45(8):1354-63. [Medline].
Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004 Jun 8. 109(22):2807-16. [Medline].
Kathare PA, Muthuswamy KS, Sadasivan J, Calumbar N, Koneti NR. Incessant ventricular tachycardia due to multiple cardiac rhabdomyomas in an infant with tuberous sclerosis. Indian Heart J. 2013 Jan-Feb. 65(1):111-3. [Medline].
Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 9. 61(14):1527-35. [Medline].
Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol. 2013 Jun 1. 6(3):579-87. [Medline].
Moore JP, Seki A, Shannon KM, Mandapati R, Tung R, Fishbein MC. Characterization of Anatomic Ventricular Tachycardia Isthmus Pathology after Surgical Repair of Tetralogy of Fallot. Circ Arrhythm Electrophysiol. 2013 Jul 24. [Medline].
Song MK, Baek JS, Kwon BS, et al. Clinical spectrum and prognostic factors of pediatric ventricular tachycardia. Circ J. 2010 Sep. 74(9):1951-8. [Medline].
Sun J, Shah N, Karpawich PP, Humes R. Refractory idiopathic ventricular tachycardia in a newborn treated successfully with phenytoin: old therapies are still effective in the current era. Pediatr Cardiol. 2011 Jan. 32(1):76-7. [Medline].
Thomas V, Lawrence D, Kogon B, Frias P. Epicardial ablation of ventricular tachycardia in a child on venoarterial extracorporeal membrane oxygenation. Pediatr Cardiol. 2010 Aug. 31(6):901-4. [Medline].
Zachariah JP, Colan SD, Lang P, et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail. 2012 Jul 1. 5(4):462-6. [Medline]. [Full Text].
Cassel-Choudhury GN, Aydin SI, Toedt-Pingel I, et al. Arrhythmias in the paediatric intensive care unit: a prospective study of the rates and predictors of arrhythmias in children without underlying cardiac disease. Cardiol Young. 2015 Oct. 25 (7):1281-9. [Medline].
Wu L, Tian H, Wang F, Liang X, Chen G. Successful ablation of incessant idiopathic right ventricular tachycardia arising from unusual sites in children. Cardiol Young. 2015 Jul 13. 1-8. [Medline].
Mark E Alexander, MD Assistant Professor, Department of Pediatrics, Children’s Hospital of Boston and Harvard Medical School
Mark E Alexander, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society
Disclosure: Nothing to disclose.
Charles I Berul, MD Professor of Pediatrics and Integrative Systems Biology, George Washington University School of Medicine; Chief, Division of Cardiology, Children’s National Medical Center
Charles I Berul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society, Society for Pediatric Research
Disclosure: Received research grant from: Medtronic.
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Hugh D Allen, MD Professor, Department of Pediatrics, Division of Pediatric Cardiology and Department of Internal Medicine, Ohio State University College of Medicine
Hugh D Allen, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Echocardiography, Society for Pediatric Research, Society of Pediatric Echocardiography, Western Society for Pediatric Research, American College of Cardiology, American Heart Association, American Pediatric Society
Disclosure: Nothing to disclose.
Howard S Weber, MD, FSCAI Professor of Pediatrics, Section of Pediatric Cardiology, Pennsylvania State University College of Medicine; Director of Interventional Pediatric Cardiology, Penn State Hershey Children’s Hospital
Howard S Weber, MD, FSCAI is a member of the following medical societies: Society for Cardiovascular Angiography and Interventions
Disclosure: Received income in an amount equal to or greater than $250 from: Abbott Medical .
Christopher Johnsrude, MD, MS Chief, Division of Pediatric Cardiology, University of Louisville School of Medicine; Director, Congenital Heart Center, Kosair Children’s Hospital
Disclosure: Nothing to disclose.
Pediatric Ventricular Tachycardia Overview of Ventricular Arrhythmias
Research & References of Pediatric Ventricular Tachycardia Overview of Ventricular Arrhythmias|A&C Accounting And Tax Services